Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Efinopegdutide in Healthy Obese Participants
NCT06701305Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efinopegdutide in obesity (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event at 184 days, Number of Participants Who Discontinue Study Treatment Due to an Adverse Event at 184 days and 3 more. Started Jun 2024; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06701305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701305.